Mankind Pharma Limited has announced the acquisition of the brand Rivotril from Roche for the Indian market. With this move, the company gains exclusive rights to manufacture, market, and distribute the product across the country.
Rivotril, the innovator and reference brand of clonazepam, is widely prescribed for managing neurological and psychiatric conditions. Moreover, clinicians regard it as a “textbook brand” due to its strong clinical legacy and widespread recognition.
Strengthening Presence in CNS Therapy
This acquisition significantly enhances Mankind Pharma’s footprint in the central nervous system (CNS) therapy segment. In addition, it complements the company’s existing neuro portfolio and reinforces its position among specialists treating neurological disorders.
By adding a well-established and trusted brand like Rivotril, the company aims to expand treatment options for patients while strengthening its engagement with healthcare professionals.
Focus on Chronic and Specialty Therapies
Over the past few years, Mankind Pharma has steadily increased its focus on chronic therapies. It has achieved this through new product launches, in-licensing partnerships, and strategic portfolio expansions across key therapeutic areas.
Consequently, chronic therapies now contribute a growing share of the company’s overall business. This shift reflects its strategy to scale specialty segments and deepen relationships with specialists and key opinion leaders.
Leadership Perspective
As per the press release, Atish Majumdar, Senior President, Sales & Marketing, Specialty Business at Mankind Pharma, emphasised that the acquisition aligns with the company’s long-term strategy.
He noted that the company sees strong opportunities to build on this platform through potential line extensions. Furthermore, it aims to address evolving patient and physician needs within the CNS therapy space.
Distribution and Market Reach
Mankind Pharma plans to leverage its extensive nationwide distribution network and large field force to expand access to Rivotril across India. The company currently engages with over five lakh doctors and maintains a strong prescription presence in both urban and semi-urban markets.
As a result, it is well positioned to drive deeper market penetration and support physicians in improving patient outcomes.
Conclusion:
Overall, this acquisition marks a strategic step in Mankind Pharma’s journey to strengthen its specialty portfolio. By integrating a trusted CNS brand like Rivotril, the company aims to enhance treatment accessibility and contribute to better management of neurological and psychiatric conditions across India.